About BridgeBio Pharma BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat rare diseases at their source. Founded in 2015 by a team of industry veterans who previously brought more than a dozen products to market, BridgeBio has built a robust portfolio of ten transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage. With a commitment to scientific excellence and rapid execution, BridgeBio aims to translate today's discoveries into tomorrow's medicines. SOURCE BridgeBio Pharma Related Links http://bridgebio.com